Location · Atlanta, GA
Clinical trials in Atlanta, GA
636 recruiting studies have a site in the Atlanta area, and 148 of them accept healthy volunteers. The area includes Decatur, Marietta, Sandy Springs, Alpharetta, Roswell, Lawrenceville and nearby cities.
636 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
More recruiting studies (pay not posted)
- RecruitingPhase 2/Phase 3
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Blueprint Medicines Corporation
- Location
- Birmingham, AL + 14 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves
Edwards Lifesciences
- Location
- San Francisco, CA + 26 other US sites
- Eligibility basics
- Any age listed
- RecruitingPhase 3
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Eli Lilly and Company
- Location
- Hartford, CT + 10 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 2/Phase 3
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
Merck Sharp & Dohme LLC
- Location
- Wilmington, DE + 7 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
AstraZeneca
- Location
- Sacramento, CA + 26 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
Eli Lilly and Company
- Location
- Orange, CA + 19 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study of Brenipatide in Adult Participants With Schizophrenia
Eli Lilly and Company
- Location
- Little Rock, AR + 31 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
Alkermes, Inc.
- Location
- Cullman, AL + 21 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)
Alkermes, Inc.
- Location
- Brandon, FL + 14 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
Novo Nordisk A/S
- Location
- Gilbert, AZ + 18 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)
Alkermes, Inc.
- Location
- Little Rock, AR + 17 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
Eli Lilly and Company
- Location
- Birmingham, AL + 28 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
Zenith® Fenestrated+ Clinical Study
Cook Research Incorporated
- Location
- Birmingham, AL + 29 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Hoffmann-La Roche
- Location
- Loma Linda, CA + 8 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Gilead Sciences
- Location
- Birmingham, AL + 53 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Cabaletta Bio
- Location
- Orange, CA + 17 other US sites
- Eligibility basics
- Ages 12–65
- RecruitingPhase 3
This Study Will Evaluate the Effectiveness of NTX-001, a Surgical Nerve Repair Product When Used in People With Upper Extremity Nerve Lacerations.
Neuraptive Therapeutics Inc.
- Location
- Orlando, FL + 22 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Celgene
- Location
- Huntsville, AL + 31 other US sites
- Eligibility basics
- Ages 55–90
- Recruiting
Alleviant ALLAY-HFrEF Study
Alleviant Medical, Inc.
- Location
- Los Angeles, CA + 38 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Calico Life Sciences LLC
- Location
- Birmingham, AL + 33 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingPhase 2
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Seaport Therapeutics
- Location
- Chino, CA + 26 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche
- Location
- Aurora, CO + 7 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche
- Location
- Birmingham, AL + 52 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
Bristol-Myers Squibb
- Location
- Anaheim, CA + 12 other US sites
- Eligibility basics
- Ages 13–17